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Abstract Low-density detergent-insoluble membrane domains
contain caveolin-1 and are enriched in a phospholipase D activity
that is not PLD1. Here we show that caveolin-rich fractions,
prepared from HaCaT human keratinocytes by either detergent-
based or detergent-free methods, contain PLD2. Caveolar
membrane PLD activity is stimulated 2-fold by low concentra-
tions (10^30 WM) of the caveolin-1 and caveolin-2 scaffolding
domain peptides, whereas it is inhibited at higher concentrations
of the peptides. Immunoisolated HA-tagged PLD1 and PLD2
are not stimulated by the peptides, although both enzymes retain
sensitivity to their inhibitory effect. Down-regulation of caveolin-
1 expression by treatment of the cells with acetyl-leucyl-leucyl-
norleucinal decreased caveolar PLD activity by 50%. Similarly,
expression of an active form of the sterol regulatory element-
binding protein (SREBP1ÿ490) down-regulated caveolin-1 ex-
pression by 50% and decreased caveolar PLD activity by 60%.
These data identify the PLD activity in caveolin-rich membranes
as PLD2 and provide in vivo evidence suggesting that caveolin-1
regulates PLD2 activity.
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1. Introduction
Phospholipase D (PLD) is a signal-activated enzyme. PLD
activity is low in unstimulated cells and it is activated upon
cell stimulation by a broad range of stimuli [1]. Mammalian
PLD activities catalyze hydrolysis mainly of phosphatidylcho-
line (PC) and phosphatidylethanolamine [2]. The PLD prod-
uct, phosphatidic acid (PA), is believed to act as a regulator of
cellular signal transduction and membrane tra⁄c processes,
although the identity of its molecular targets is still unknown
[3,4]. Molecular cloning has identi¢ed two mammalian PLD
genes, namely PLD1 and PLD2, that have approximately 50%
overall sequence homology [5]. PLD1 and PLD2 di¡er in their
tissue distribution, subcellular localization and regulation [6].
PLD1 was shown to localize mainly to secretory granules, late
endosomes and lysosomes [7,8] and to colocalize with cyto-
skeletal components [9]. PLD2 was found to be associated
with the plasma membrane in quiescent cells, and to trans-
locate to an endosomal-like compartment upon cell stimula-
tion [10]. Recently we have reported that detergent-insoluble,
caveolin-rich membrane domains are enriched in PLD activity
[11]. Immunoblot analysis of caveolar fractions prepared
from various cell lines has indicated that the activity is not
due to PLD1, and that it is modulated by expression of cav-
eolin-1 in vivo and by a caveolin-1-derived peptide in vitro
[11]. These data raised the possibility that PLD is localized in
caveolae and may be involved in caveolae-dependent cell func-
tions.
Caveolae are small (50^100 nm) £ask-shaped invaginations
of the plasma membrane [12]. Caveolin is a 21^24 kDa pro-
tein component of the caveolar coat structure [13]. Three cav-
eolin family members have recently been cloned and were
designated caveolin-1, caveolin-2 and caveolin-3 [14]. Caveo-
lin-1 and -2 are usually coexpressed in tissues, whereas cav-
eolin-3 is a muscle-speci¢c isoform. Caveolin-1 was shown to
form homo-oligomers comprising 14^16 monomers, as well as
hetero-oligomers with caveolin-2 [15^17]. Caveolae have been
implicated in sequesteration of many signaling molecules, in-
cluding cell surface receptors (e.g. receptor tyrosine kinases, G
protein-coupled receptors), transducers (e.g. heterotrimeric G
proteins and small GTPases) and e¡ectors (e.g. cytoplasmic
tyrosine kinases, protein kinase C) [14]. A small domain of
about 20 amino acids, located in the N-terminal juxtamem-
brane region of the caveolin sequences, was shown to serve as
a structural sca¡old responsible for these interactions [14].
Another important function of caveolae is in mediating cho-
lesterol e¥ux from cells [18]. Indeed, expression of caveolin-1
is down-regulated by the sterol regulatory element-binding
protein (SREBP) pathway that regulates the mevalonate path-
way of cholesterol biosynthesis [19]. Finally, caveolae have
been implicated in clathrin-independent, dynamin-dependent,
endocytosis ([20] and citations therein).
PLD has been implicated in many of the above phenomena,
particularly in cell signaling and membrane transport pro-
cesses. It was therefore reasonable to assume that the PLD
activity present in caveolin-rich membranes may be involved
in mediating or regulating one or more caveolae-dependent
functions. As a ¢rst step in evaluating this hypothesis, the
present work was designed to identify the PLD isoform that
localizes to caveolae and to explore its functional interac-
tion(s) with caveolin-1 and caveolin-2.
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2. Materials and methods
2.1. Cell culture
HaCaT, a human keratinocyte cell line [21] was kindly provided by
Dr. Norbert Fusenig (Deutcheskrebsforschungszentrum, Heidelberg,
Germany). HaCaT cells were cultured at 37‡C in a humidi¢ed atmos-
phere containing 5% CO2 in Dulbecco’s modi¢ed Eagle’s medium
supplemented with 10% (v/v) fetal calf serum (FCS) and antibiotics
(penicillin/streptomycin). CHO cells were grown in Alfa+ medium
supplemented with 10% FCS and antibiotics. Stable transfectants
overexpressing mouse PLD2 were prepared as described previously
[11]. COS-7 cells were grown in the same media and conditions as
HaCaT cells. Transient transfections with human HA-hPLD1 or HA-
mPLD2 in pCGN vectors (kindly provided by Drs. Michael Frohman
and Andrew Morris) were performed using the DEAE-dextran-
chloroquine protocol [22].
2.2. Generation of SREBP-transfected HaCaT cells
cDNA encoding human SREBP1ÿ490 in pCMV5 (kindly provided
by Dr. Tim Osborne) was subcloned into a plasmid for stable trans-
fection (pcDNA3, Invitrogen) using EcoRI and XbaI restriction sites,
and utilized for stable transfection of HaCaT cells. Four Wg of DNA
were transfected per 35-mm, 70% con£uent dish using LipofectAM-
INE (Life Technologies, Inc.) according to the manufacturer’s instruc-
tions. Cells were selected with 400 Wg/ml G418 (Calbiochem) in
the culture medium; individual clones were grown and used after
3 months.
2.3. Isolation of low-density Triton X-100-insoluble membrane domains
Low-density Triton X-100-insoluble membrane domains were iso-
lated from cultured cells essentially as described in [23]. Brie£y, cell
monolayers (two con£uent 150-mm dishes; V3U107 cells) were
scraped in 1 ml of ice-cold lysis bu¡er containing 25 mM MES, pH
6.5, 0.15 M NaCl, 1 mM phenylmethylsulfonyl £uoride, 10 Wg/ml
aprotinin, 10 Wg/ml leupeptin, 1% Triton X-100. After homogeniza-
tion, cell extracts were adjusted to 40% sucrose by addition of 1 ml of
the above bu¡er (minus Triton X-100) containing 80% sucrose, and
placed at the bottom of a 12-ml ultracentrifuge tube. A discontinuous
gradient was formed above the lysate by adding 4 ml each of 30 and
5% sucrose solutions, and the tubes were centrifuged at 190 000Ug
(39 000 rpm) for 16^20 h at 4‡C in an SW-41 rotor. Fractions (0.9 ml)
were collected beginning at the top of the gradient. The pellet was
resuspended in 0.9 ml of MES^NaCl bu¡er. Fractions were snap
frozen in liquid nitrogen and stored at 380‡C. The protein content
of each fraction was determined according to a modi¢ed Lowry pro-
cedure using a commercially available kit (Bio-Rad).
2.4. Detergent-free isolation of caveolin-rich membrane fractions
Detergent-free puri¢cation of caveolin-rich membrane fractions was
performed essentially as described in [24]. Two con£uent 150-mm
dishes, washed twice with ice-cold phosphate-bu¡ered saline, were
scraped into 2 ml of sodium carbonate bu¡er (500 mM sodium car-
bonate, pH 11, 25 mM MES, 150 mM NaCl; with addition of 1 mM
phenylmethylsulfonyl £uoride, 10 Wg/ml aprotinin, 10 Wg/ml leupep-
tin). Cells were homogenized utilizing a loose-¢tting Dounce homog-
enizer (20 strokes) followed by homogenization for 20 s in a Polytron
tissue grinder (Kinematica AG Littau, Switzerland) and sonication by
a single continuous pulse of 30 s, at setting 2, followed by 15 2-s
bursts at setting 4 (Heat System, Ultrasonics). The homogenate was
then adjusted to 45% sucrose by the addition of 2 ml of 90% sucrose
prepared in MES^NaCl bu¡er (25 mM MES, pH 6.5, 0.15 M NaCl)
and placed at the bottom of an ultracentrifuge tube. A 5^35% dis-
continuous sucrose gradient was formed above the 45% layer, by add-
ing 4 ml of 35% sucrose and 4 ml of 5% sucrose (both in MES^NaCl
bu¡er) and centrifuged at 39 000 rpm for 16^20 h in an SW-41 rotor
(Beckman Instruments). Twelve 1-ml fractions were collected from the
top. Fraction 13, the insoluble pellet, was resuspended in 1 ml of
MES^NaCl bu¡er. Fractions were snap frozen in liquid nitrogen
and stored at 380‡C.
2.5. Assay of phospholipase D in vitro
The activity of PLD was determined with 1-acyl-2-[6-N-(7-nitroben-
zo-2-oxa-1,3 diazol-4-yl)amino]caproyl-phosphatidylcholine (C6-
NBD-phosphatidylcholine) (Avanti Polar Lipids) as substrate, mea-
suring the production of C6-NBD-phosphatidylpropanol. The assay
was carried out essentially as described previously [25], with minor
modi¢cations. Brie£y, the reaction mixtures (120 Wl) contained 50 mM
Na^HEPES, pH 7.2, 0.3 mM C6-NBD-PC, 150 mM 1-propanol, and
2 mol% PIP2 (Boehringer Mannheim). The amount of protein present
in the assay varied when PLD was determined directly in aliquots of
gradient fractions. The assay of PLD activity in immunoprecipitates
was performed directly on the beads (40 Wl). Reactions were carried
out for 60 min at 37‡C. Termination, separation of the products by
thin layer chromatography and quanti¢cation were carried out as
described previously [25]. Results are expressed in terms of C6-
NBD-phosphatidylpropanol £uorescence units produced.
2.6. Immunoblot analysis of caveolins and PLDs
Aliquots taken from each of the sucrose density gradient fractions
were separated by SDS^PAGE. Proteins were transferred to nitrocel-
lulose membranes and blocked by incubation with 5% skim milk (w/v)
in phosphate-bu¡ered saline containing 0.1% Triton X-100 (T-PBS)
for 1 h. Immunoblot analysis of caveolins was carried out with mono-
clonal antibodies to caveolin-1 (clone 2297, Transduction Laborato-
ries) and caveolin-2 (clone 65, Transduction Laboratories). Immuno-
blot analysis of PLDs was performed with polyclonal anti-hPLD1
serum (#3074; directed against a peptide that corresponds to residues
675^688 of human PLD1) and anti-hPLD2 (#58) raised against a
peptide corresponding to human PLD2 residues 523^534, prepared
according to [26]. Antibodies were utilized in a dilution of 1:2000 in
T-PBS. The blots were then washed extensively and incubated with
horseradish peroxidase-linked goat anti-rabbit or goat anti-mouse
IgG. Bands were visualized by enhanced chemiluminescence using a
commercially available kit (Amersham Pharmacia Biotech). Densi-
tometry quanti¢cation of ¢lms was performed using the Quantity
One v.3 software.
2.7. Immunoprecipitation
COS-7 cells transfected with Ha-tagged PLD1 or PLD2 were har-
vested 72 h after transfection. Cells were washed twice with ice-cold
PBS, scraped in MES bu¡er containing 1% Triton X-100 and protease
inhibitors, and snap frozen for storage at 380‡C until use. For im-
munoprecipitation, cell lysates were thawed, diluted with 2Uimmuno-
precipitation bu¡er (IP bu¡er: 1% Triton X-100, 0.5% NP-40, 150
mM NaCl, 10 mM Tris^HCl pH 7.4, 1 mM EDTA, 1 mM EGTA)
and protease inhibitors were added to ¢nal concentration of 1 mM
phenylmethylsulfonyl £uoride, 10 Wg/ml aprotinin and 10 Wg/ml leu-
peptin. Lysates were placed on ice for 30 min and then centrifuged at
15 000Ug for 15 min. Supernatants (10 Wg of protein per sample) were
incubated with 4 Wg of monoclonal anti-HA antibodies (clone 12CA5,
Boehringer Mannheim) and 40 Wl of protein A/G PLUS-agarose (San-
ta Cruz Biotechnology) for 4 h at 4‡C. Immune complexes were re-
covered by centrifugation and washed four times with IP bu¡er, and
once with 10 mM Tris^HCl, pH 7.4. Immunoprecipitates were as-
sayed for PLD activity and after phospholipid separation the beads
were dried in a speed vacuum and 40 Wl of 2Usample bu¡er for SDS^
PAGE was added. Proteins were separated by SDS^PAGE and im-
munoprecipitation was con¢rmed by immunoblot analysis with anti-
HA antibodies.
2.8. Caveolin sca¡olding domain peptides
Two caveolin-derived peptides, the caveolin-1 sca¡olding domain
peptide (HGIWKASFTTFTVTKYWFYR; amino acid residues 82^
101) and the caveolin-2 sca¡olding domain peptide (DKVWICSHAL-
FEISKYVMYK; amino acid residues 54^73) were prepared by con-
ventional solid phase synthesis protocols in the laboratory of Prof. M.
Fridkin, Dept. of Organic Chemistry, Weizmann Institute of Science.
Peptides were dissolved in water to yield stock solutions of 10 mM
which were diluted to a ¢nal concentration of 1^100 WM at the time of
assay. The proportion of the identity in the corresponding amino acid
residue among the sca¡olding domain peptides is 35%, and similarity
is 55%.
3. Results
Caveolin-rich membrane domains, isolated as low-density
detergent-insoluble fractions on a discontinuous sucrose den-
sity gradient, are enriched in a PLD activity that is not PLD1
[11]. To positively identify the PLD isoform in these fractions
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we employed anti-PLD2 antibodies directed against human
PLD2 residues 523^534. Fig. 1A, B documents the distribu-
tion of PLD1 and PLD2, in comparison with the distribution
of caveolin-1 and caveolin-2, in Triton X-100 lysates of Ha-
CaT cells fractionated on a sucrose density gradient. A single
light-scattering band corresponding to low-density membrane
domains was observed, mainly in fractions 5 and 6. Equal-
volume aliquots from each of the 12 sucrose gradient fractions
were subjected to SDS^PAGE. Immunoblot analysis with spe-
ci¢c, monoclonal antibodies to caveolin-1 and caveolin-2 in-
dicated that low-density fractions 5^7 (caveolar membranes,
C) contain all the caveolin-1 and most of the caveolin-2 im-
munoreactivity (Fig. 1A). The high-density fractions 8^11
(non-caveolar fractions, NC) were devoid of caveolin-1, and
contained little caveolin-2 immunoreactivity (less than 2% of
the total). Con¢rming our previous observations, PLD1 im-
munoreactivity is exclusively localized in non-caveolar frac-
tions. In contrast, a PLD2 immunoreactive band appears in
both non-caveolar fractions (fractions 8^12) as well as in the
caveolin-containing fractions (namely fractions 5^7; Fig. 1B).
The fraction of the total PLD2 immunoreactivity that local-
izes to the caveolin-containing fractions amounts to 15% (Fig.
1B). This is roughly equivalent to the fraction of PLD activity
previously measured in this part of the gradient [11]. Immu-
noblot analysis of samples of pooled caveolar (C), non-cav-
eolar (NC) and total cell lysates (TCL), containing equal
amounts of protein, con¢rms the absence and presence of
PLD1 and PLD2, respectively, in the caveolar fraction (Fig.
1C). However, we did not observe an enrichment of the PLD2
protein band in caveolar fractions.
Caveolin-rich membranes can be prepared by a detergent-
free method that involves homogenization of cell lysates at a
high concentration of sodium carbonate, followed by sonica-
tion and isolation of caveolar membrane particles on a su-
Fig. 1. Distribution of PLD immunoreactivity in Triton X-100 su-
crose density gradient fractions from HaCaT cells. Triton X-100 ly-
sates were prepared from HaCaT cells and fractionated by £otation
in sucrose density gradient. A and B: Equal-volume aliquots (40 Wl)
of the fractions were separated for analysis of caveolin-1 and caveo-
lin-2 immunoreactivity (A) and PLD1 immunoreactivity (B). For
PLD2 immunoreactivity, 200 Wl of each gradient fraction was pre-
cipitated in ice-cold acetone and separated on SDS^PAGE for im-
munoblot analysis (B). Separated proteins were transferred onto ni-
trocellulose membranes and immunoblotted as described in Section
2. Bands on ¢lm were quanti¢ed using Quantity One v.3 program.
C: Equal loads of protein (20 Wg) of caveolar fractions (C; corre-
sponding to fractions 5, 6, and 7 from the gradient), non-caveolar
fractions (NC; fractions 8^11) and total cell lysate (TCL) were im-
munoblotted with caveolin and PLD antibodies as indicated.
Fig. 2. Distribution of PLD immunoreactivity in detergent-free su-
crose density gradient fractions from HaCaT cells. Detergent-free,
sodium carbonate-based lysates were prepared from HaCaT cells
and fractionated by £otation in sucrose density gradient. A and B:
Equal-volume aliquots (40 Wl) of the fractions were separated for
analysis of caveolin-1 and caveolin-2 immunoreactivity (A) and
PLD1 immunoreactivity (B). For PLD2 immunoreactivity, 200 Wl of
each gradient fraction was precipitated in ice-cold acetone and sepa-
rated on SDS^PAGE for immunoblot analysis (B). Separated pro-
teins were transferred onto nitrocellulose membranes and immuno-
blotted as described in Section 2. Bands on ¢lm were quanti¢ed
using Quantity One v.3 program. C: Equal-volume aliquots (20 Wl)
were assayed for PLD activity as described in Section 2. C, caveolar
membranes (fractions 4, 5 and 6 from the gradient); NC, non-cav-
eolar fractions (fractions 7^12); P, pellet.
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crose density gradient, based on their intrinsic low buoyant
density [24]. Fig. 2A shows the distribution of caveolin-1 and
-2 along a sodium carbonate sucrose density gradient, which is
similar to that shown in Fig. 1. In contrast, the distribution of
PLD1 and PLD2 is quite di¡erent in this type of caveolar
preparation. Whereas most of the PLD1 immunoreactivity is
still localized in non-caveolar fractions, some PLD1 (7^10%)
can be found in caveolin-containing fractions. PLD2 immu-
noreactivity dramatically shifted into caveolar membranes,
such that nearly 60% of the cellular PLD2 co-fractionated
with the caveolin markers (Fig. 2B). The detergent-free meth-
od also resulted in a nearly complete localization of PLD
activity in caveolin-containing membranes (Fig. 2C). These
data indicate that the localization of PLD activity in caveolar
membranes is not due to a detergent-induced redistribution of
the enzyme. Furthermore, the data con¢rm that caveolar PLD
activity is largely due to PLD2. Comparison of the distribu-
tion of PLD activity and PLD1 immunoreactivity in either
gradient shows major discrepancies. In Triton X-100 sucrose
density gradients, caveolar membranes evince high PLD ac-
tivity in the absence of PLD1 immunoreactivity ([11] and Fig.
1). On the other hand, in sodium carbonate sucrose density
gradients, non-caveolar fractions have high PLD1 immunore-
activity in the absence of PLD activity. It may thus be con-
cluded that the major caveolar PLD isoform is PLD2.
The speci¢c activity of caveolar PLD is much higher than
that of other fractions, indicating the relative enrichment of
the enzyme in these membrane domains [11]. However, as
shown in Fig. 1C, the intensity of the PLD2 immunoreactive
band in equal protein samples of pooled caveolar and non-
caveolar fractions is indistinguishable. These ¢ndings have
raised the possibility that the caveolar membrane PLD2 is
in a more activated state, relative to other cell membranes.
Caveolin-1 expression has been shown to elevate PLD activity
in caveolar fractions and the caveolin-1 sca¡olding domain
peptide was shown to modulate caveolar PLD activity in vitro
[11]. To test the hypothesis that PLD2 is regulated by caveo-
lin, and to identify the caveolin isoform involved, we exam-
ined the e¡ect of sca¡olding domain peptides derived from
caveolin-1 and caveolin-2. We ¢rst examined the e¡ect of
the caveolin-1 and -2 sca¡olding domain peptides on PLD
activity in fraction 5 of a HaCaT cell Triton X-100 sucrose
density gradient. This fraction was shown to have the highest
caveolin-1 and -2 content as well as the highest PLD activity
(cf. Fig. 1A, B and [11], respectively). Stimulation of PLD
activity by the caveolin-1 sca¡olding domain peptide (at a
stimulatory concentration of 10 WM) was found to depend
Fig. 3. Regulation of caveolar PLD activity by caveolin peptides.
A: Increasing amounts of fraction 5 (0^8 Wg of protein) from a Tri-
ton X-100-based caveolae preparation derived from HaCaT cells
were incubated for PLD assay in the absence (control; open
squares) or presence of caveolin-1 sca¡olding domain peptide (10
WM) (caveolin-182ÿ101 ; gray circles) or caveolin-2 sca¡olding domain
peptide (10 WM) (caveolin-254ÿ73 ; solid squares). B: Dose-dependent
e¡ect of caveolin-1 sca¡olding domain peptide (0^100 WM) (caveo-
lin-182ÿ101 ; gray circles) and caveolin-2 sca¡olding domain peptide
(0^100 WM) (caveolin-254ÿ73 ; solid squares) on PLD activity in frac-
tion 5 (1 Wg of protein per assay) of Triton X-100-based caveolae
preparation from HaCaT cells. Mean þ S.E.M. from two indepen-
dent experiments in triplicates.
Fig. 4. E¡ect of caveolin sca¡olding domain peptides on PLD1 and
PLD2 activity. Immunopuri¢ed HA-tagged PLD1 and PLD2 were
assayed for PLD activity as described in Section 2. A: PLD1 activ-
ity in immunoprecipitates in the absence (control, open bar), and
presence of increasing concentrations of caveolin-1 sca¡olding do-
main peptide (caveolin-182ÿ101 ; gray bars) and caveolin-2 sca¡olding
domain peptide (caveolin-254ÿ73 ; solid bars). Mean þ standard errors
from four independent experiments. B: PLD2 activity in immuno-
precipitates in the absence (control, open bar), and presence of in-
creasing concentrations of caveolin-1 sca¡olding domain peptide
(caveolin-182ÿ101 ; gray bars) and caveolin-2 sca¡olding domain pep-
tide (caveolin-254ÿ73 ; solid bars). Concentrations of the peptides
were as indicated. Mean þ S.E.M. from three independent experi-
ments.
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on the amount of membrane protein in the assay (Fig. 3A). A
maximal e¡ect (up to 80% stimulation) was observed at 1 Wg
protein of fraction 5, whereas there was little e¡ect at 5 and 10
Wg of membrane protein. In contrast, the caveolin-2 sca¡old-
ing domain peptide caused a 2-fold stimulation of caveolar
PLD activity that was largely independent of membrane pro-
tein content in the assay (Fig. 3A). Next we tested the con-
centration-dependent response of caveolin-1 and -2 sca¡olding
peptides on caveolar PLD activity. As shown in Fig. 3B, both
peptides exhibit a bimodal e¡ect on PLD activity. Caveolin-1
sca¡olding domain peptide has a stimulatory e¡ect at a con-
centration range of 2^25 WM and an inhibitory e¡ect at higher
concentrations. Complete inhibition of caveolar PLD activity
was obtained at 100 WM. Caveolin-2 sca¡olding peptide is
stimulatory at the 10^50 WM concentration range. Maximal
simulation was seen at 20 WM and the inhibitory e¡ect at
higher concentration was not as strong as for caveolin-1 scaf-
folding peptide (Fig. 3B). Hence, both caveolin-1 and caveo-
lin-2 may modulate PLD activity in caveolar membranes, with
the caveolin-1 peptide being more potent but less e¡ective
than the caveolin-2 peptide. This fact, together with the mem-
brane protein dependence of the e¡ect, suggests that caveolin-
1 may stimulate PLD2 indirectly, perhaps via an interaction
with another caveolae constituent.
To further investigate the interactions of PLD isoenzymes
with caveolin, we immunoisolated HA-tagged PLD1 and HA-
PLD2 from transiently transfected COS-7 cells using anti-HA
antibodies. PLD1 and PLD2 activities were measured in the
immune complexes under the exact same conditions in order
to avoid possible e¡ects due to isoform-speci¢c PLD-cofactor
interactions. Consequently, PLD1 activity was measured in
the absence of added ADP-ribosylation factor, RhoA or pro-
tein kinase C and therefore was quite low. Neither of caveolin
sca¡olding peptides had a stimulatory e¡ect on PLD1 activity,
and both had an inhibitory e¡ect (40^60%) at a high concen-
tration (100 WM) (Fig. 4A). Basal PLD2 activity was much
higher than that of PLD1 but, like PLD1 activity, it was not
stimulated by the caveolin sca¡olding peptides. PLD2 activity
was inhibited at a concentration of 100 WM of the caveolin-1
and -2 sca¡olding domain peptides by 60 and 40%, respec-
tively (Fig. 4B). These data indicate that HA-tagged PLD1
and PLD2 are quite similar in their interaction with caveolin
sca¡olding peptides. However, the ability of these peptides to
stimulate PLD activity is lost upon immunoisolation of PLD,
reinforcing the hypothesis that caveolin modulates PLD activ-
ity indirectly.
It was therefore important to seek in vivo evidence for the
regulation of PLD activity by caveolin. Previously we have
shown that expression of recombinant caveolin-1 had mark-
edly elevated PLD activity in the caveolin-rich fractions de-
rived from v-Src-transformed NIH 3T3 cells, but had little
e¡ect on PLD activity in the high-density, non-caveolar frac-
tions [11]. SREBP, a transcriptional regulator of the mevalo-
nate pathway [27], was shown to be a negative regulator of
caveolin-1 expression [19]. The cysteine protease inhibitor
N-acetyl-leucyl-leucyl-norleucinal (ALLN) prevents degrada-
tion of the mature form of SREBP and exerts a negative e¡ect
on caveolin-1 expression [19]. Incubation of HaCaT cells with
Fig. 5. E¡ect of ALLN on caveolin-1 expression and PLD activity
in HaCaT cells. HaCaT cell were incubated in the absence (control;
open bars) or presence of 10 WM ALLN (solid bars) for 24 and 48
h as indicated. Cells were harvested in Triton X-100 lysis bu¡er and
subjected to separation on sucrose density gradients as described in
Section 2. A: Caveolin-1 immunoreactivity in caveolar fractions
(pooled fraction 5, 6 and 7). B: PLD-speci¢c activity in caveolar
fractions (C), non-caveolar fractions (NC), insoluble pellet (P) and
total cell lysates (TCL) in cells treated for 48 h with 10 WM ALLN
(black bars).
Fig. 6. E¡ect of SREBP1ÿ490 transfection on caveolin-1 expression
and PLD activity in HaCaT cells. HaCaT cells were transfected
with SREBP1ÿ490 as described in Section 2. After selection, isolated
clones designated HS3 and HS6 were examined for caveolin-1,
PLD1, and PLD2 immunoreactivity (A) and for PLD activity in
pooled fractions from the Triton X-100 sucrose density gradients
(B). C, caveolar membranes; NC, non-caveolar fractions; P, insolu-
ble pellet; TCL, total cell lysate. Mean þ S.E.M. from two individu-
al experiments in triplicates.
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10 WM ALLN lowered caveolin-1 immunoreactivity in cell
lysates by 25% after 24 h, and by nearly 50% after 48 h
(Fig. 5A). The ALLN concentration used did not cause cell
death within 72 h as measured by MTT cytotoxicity assay
(data not shown). PLD activity assayed in pooled fractions
of Triton X-100 sucrose density gradient was markedly de-
creased (up to 50%) in caveolar membranes after 48 h of
ALLN treatment (Fig. 5B). In contrast, PLD activity in the
non-caveolar fractions, pellet and total cell lysate showed little
change. Similar results were obtained after 72 h with ALLN
(data not shown).
To further investigate the regulation of caveolar PLD by
caveolin-1 expression levels, HaCaT cells were stably trans-
fected with a cDNA corresponding to the mature, active
form of SREBP, namely SREBP1ÿ490. Two clones, which dif-
fer in caveolin-1 expression levels, were isolated and desig-
nated HS3 and HS6. As shown in Fig. 6A, caveolin-1 levels
in clone HS3 and HS6 were lowered by 30% and 50%, respec-
tively. PLD1 and PLD2 immunoreactivity in the clones was
not altered. In contrast, PLD activity in caveolar membranes
(C) from the SREBP1ÿ490-expressing clones was decreased.
The extent of the decrease in PLD activity (60%) was more
pronounced in the HS6 clone, in accordance with the larger
decrease of caveolin-1 levels in these cells. Once again, there
was no signi¢cant change in PLD activity in the non-caveolar
fractions.
4. Discussion
Recently we have reported the presence of phospholipase D
activity in detergent-insoluble membranes, enriched in the
caveolar marker protein caveolin-1 [11]. The data provided
herein indicate that the major known PLD isoform present
in caveolin-enriched membranes is PLD2. PLD1 immunore-
activity was found exclusively in the high-density fractions
from the Triton X-100 sucrose density gradient, which contain
cytosolic and detergent-soluble proteins, as well as high-den-
sity nuclear and cytoskeletal protein complexes. PLD1 was
also found in detergent-insoluble fractions, corresponding to
cytoskeleton, from HL60 cells and U937 cells [9,28]. It was
recently shown that caveolin-rich membranes prepared by the
sodium carbonate detergent-free method contain PLD1 im-
munoreactivity, as well as a direct interaction of PLD1 with
caveolin-1 by co-immunoprecipitation [29]. Our results con-
¢rm that membrane fractions thus prepared contain a minor
fraction (6 10%) of cellular PLD1 immunoreactivity. How-
ever, those same fractions contain most (V60%) of the cellu-
lar PLD2. Therefore, although the possibility that PLD1 is
present in caveolar membranes cannot be ruled out entirely,
it seems that PLD2 is the major if not the only form. This
conclusion is con¢rmed by recent work showing that PLD
activity present in detergent-insoluble membranes can only
be immunoprecipitated with anti-PLD2 but not anti-PLD1
antibodies [30].
The membrane domains isolated in low-density fractions by
either one of the two methods utilized here are likely to in-
clude caveolar membranes as well as cholesterol- and sphin-
golipid-rich rafts. PLD activity is enriched in these domains
also in U937 cells (which do not express caveolin-1; [11]),
indicating that PLD does not require caveolin for targeting
to cholesterol- and sphingolipid-rich domains. However, our
previous as well as present results indicate that the activity of
PLD in these fractions is modulated by the expression level of
caveolin-1. Overexpression of caveolin-1 results in elevated
PLD activity in caveolin-rich membranes of v-Src-trans-
formed 3T3 cells [11]. Conversely, down-regulation of caveo-
lin-1 expression, by either ALLN treatment or by expression
of SREBP1ÿ490, decreases PLD activity in caveolin-rich mem-
branes of HaCaT keratinocytes (present work). These data
suggest that caveolar PLD activity is regulated by caveolin-
1. The in vitro data, showing that caveolar PLD activity is
stimulated by the caveolin-1 and caveolin-2 sca¡olding do-
main peptides, appear to be consistent with this contention.
However, immunoisolated HA-PLD2 is not stimulated by ei-
ther peptide. A reasonable interpretation of these results
would be that caveolin-1 does not interact with PLD2 directly,
i.e. that the e¡ect of caveolin-1 expression in vivo, and of its
sca¡olding peptide in vitro, are mediated via an action on
another protein. The possible identity of that protein is a
matter for speculation. One candidate is the epidermal growth
factor receptor (EGF-R). HaCaT keratinocytes express the
EGF-R [31]. The EGF-R has been localized to caveolin-rich
membrane fractions [32,33] and, furthermore, the tyrosine ki-
nase activity of the EGF-R family member, ErbB2, was
shown to be regulated by caveolin-1 [34]. PLD2 is constitu-
tively associated with EGF-R and EGF stimulates phosphor-
ylation of murine PLD2 on tyrosine-11 [35]. In conclusion, a
plausible if speculative model is that PLD2 is associated with
EGF-R in caveolin-rich membrane fractions and that caveo-
lin-1 exerts its e¡ects on PLD activity by modulation of EGF-
R activity.
What is the function of PLD2 in rafts and caveolar mem-
branes? PLD2 undergoes a serum-induced relocalization to an
endosomal-like compartment [10]. Together with data show-
ing that PLD2 is associated with and phosphorylated by
EGF-R, these results suggest that PLD2 could be involved
in a receptor-triggered endocytosis. A catalytically inactive
PLD2 mutant was reported to have a dominant negative e¡ect
on mitogen-activated protein kinase activation [36], a process
which may require receptor internalization [37]. Thus, Ro-
mero and colleagues have proposed that PLD2 is involved
in the endocytic pathway in a manner that is analogous to
the envisioned function of PLD1 in the constitutive secretory
pathway [36]. Whether PLD2 located in rafts and caveolar
membranes has a similar action remains as a major subject
for future research.
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